<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04951921</url>
  </required_header>
  <id_info>
    <org_study_id>201702080A0</org_study_id>
    <nct_id>NCT04951921</nct_id>
  </id_info>
  <brief_title>Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients at Baseline and CCRT Therapy</brief_title>
  <official_title>Precision Medicine Imaging for Cervical Cancer: Integrating MR Fingerprinting, Dynamic Nuclear Polarization (DNP)-MRI and Artificial Intelligence Radiomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this single armed, single-center, case-controlled study, the investigators will conduct a&#xD;
      prospective trial and integrate the most advanced imaging technology to medical practice,&#xD;
      attempting to solve the problem detected by radiomics approach. The investigators plan a&#xD;
      3-year project with non-randomized, single group assignment observational study design.&#xD;
      Thirty participants with diagnosed LACC that are to receive CCRT are to be recruited for this&#xD;
      prospective single institutional study from Chang Gung Memorial Hospital at Linkou (CGMH).&#xD;
      Standard-of-care MRI/CT that is required for staging will be the first line screening method.&#xD;
      A tumor biopsy and routine blood test will be obtained at the time of the initial clinic&#xD;
      visit. Participants eligible for this study will receive two investigative exams-MRF, CEST,&#xD;
      DNP-MRI MRI and Metabolomics, at baseline and the 2-week during CCRT.&#xD;
&#xD;
      The new imaging methods being tested are MRF and CEST without contrast enhancement, and&#xD;
      DNP-MRI which provides quantitative measurement of the metabolism occurring within cancer&#xD;
      cells. It also involves injection of a contrast agent-Hyperpolarized pyruvate (13C)&#xD;
      Injection. The participants will be injected with the study drug at a dose of 0.43 ml/kg and&#xD;
      then receive MRI scan.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective&#xD;
&#xD;
        1. Bridging the Gap between Imaging and Biology. DNP is the only technology that can&#xD;
           measure real-time flux of pyruvate to lactate conversion and mitochondria metabolism.&#xD;
           DNP-MRI will combine the strength of MRI (anatomy, tissue contrast via MRF, CEST and&#xD;
           DWI) and DNP (biochemistry measurement), and the blood/urine metabolomics approach, to&#xD;
           noninvasively bring more insightful information for clinical application.&#xD;
&#xD;
        2. Precision Medicine for Precision Response Prediction. Although AI or deep learning can&#xD;
           identify high-risk patient for particularly treatment (CCRT in this project), the&#xD;
           predictive model is based on prior database rather than this particular patient. The&#xD;
           investigators urgently need a non-invasive precise measurement to monitor the response&#xD;
           in a real-world situation, to reduce the treatment uncertainty, to select the most&#xD;
           cost-effective treatment. This is of paramount importance for the more advanced&#xD;
           treatment i.e. target therapy, immunotherapy etc. The investigators did not intend to&#xD;
           change the standard-of-care but the information provided by this study will help to&#xD;
           investigate the fundamental mechanisms hence providing hopes for alternative treatments.&#xD;
&#xD;
        3. Infrastructures for MR Fingerprinting and Dynamic Nuclear Polarization (DNP)-MRI&#xD;
           Research for Taiwanese researchers. The investigators are very grateful to be able to&#xD;
           install the first DNP system dedicated to human research in Asia and would like to&#xD;
           introduce this novel technology to Taiwan. Currently, human DNP study has only been&#xD;
           conducted in the USA (UCSF, MD Anderson Cancer Center and Memorial Sloan-Kettering&#xD;
           Cancer Center) and the UK (University College of London, Oxford and Cambridge) and&#xD;
           Canada (Toronto University). Based on our preliminary efforts of tracer preparation,&#xD;
           multi-nuclei scanning equipment and dedicated pulse sequences, the investigators aim to&#xD;
           build infrastructures for MR Fingerprinting and DNP-MRI Research for Taiwanese research&#xD;
           groups.&#xD;
&#xD;
      Secondary objective&#xD;
&#xD;
        1. Translate technical advancements to clinically applicable tools&#xD;
&#xD;
        2. Converge integrated information to construct the prediction model&#xD;
&#xD;
        3. Establish the delta radiomics prediction model with biological meaningfulness&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MRI size measurement of the primary tumor</measure>
    <time_frame>Change from baseline in tumor size at 3 months</time_frame>
    <description>Tumor size measurement by regular MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrent rate</measure>
    <time_frame>Follow-up for 5 years</time_frame>
    <description>Follow-up recurrent rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Hyperpolarized 13C pyruvate DNP-MRI scan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hyperpolarized 13C pyruvate through IV injection less than 1-2 minute then undergo MRI over 3-5 minutes at baseline and 2 weeks after CCRT treatment. Total 2 times of MRI scan.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hyperpolarized 13C Pyruvate</intervention_name>
    <description>Procedure: Magnetic Resonance Imaging Undergo 1H-MRI of DWI/MRF/CEST for tumor cite following by 13C DNP-MRI for spleen for 3-5 minutes after hyperpolarized 13C pyruvate injection</description>
    <arm_group_label>Hyperpolarized 13C pyruvate DNP-MRI scan</arm_group_label>
    <other_name>Hyperpolarized Carbon C 13 Pyruvate</other_name>
    <other_name>Hyperpolarized Pyruvate (13C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed carcinoma of the uterine cervix.&#xD;
&#xD;
          2. Age ≥ 20 years.&#xD;
&#xD;
          3. Clinical International Federation of Gynecology and Obstetrics (FIGO) stage IB2-IV.&#xD;
&#xD;
          4. Tumor diameter ≥ 4 cm, verified by MRI or CT.&#xD;
&#xD;
          5. Scheduled curative-intent non-surgical treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindication to MRI study (e.g. claustrophobia, cardiac pacemaker, metal implants&#xD;
             in pelvis).&#xD;
&#xD;
          2. Inadequate marrow, liver and renal functions.&#xD;
&#xD;
          3. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements.&#xD;
&#xD;
          4. Pregnant or breast-feeding women.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gigin Lin, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gigin Lin, MD, PhD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>2575</phone_ext>
    <email>giginlin@cgmh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kuan-Ying Lu, MS</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>2602</phone_ext>
    <email>fantacy52317@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan City</city>
        <state>Guishan District</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gigin Lin, MD, PhD</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2575</phone_ext>
      <email>giginlin@cgmh.org.tw</email>
    </contact>
    <contact_backup>
      <last_name>Kuan-Ying Lu, MS</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2602</phone_ext>
      <email>fantacy52317@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 21, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chang Gung Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Gigin Lin</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Hyperpolarized 13C pyruvate</keyword>
  <keyword>Dynamic nuclear polarization</keyword>
  <keyword>Artificial intelligence</keyword>
  <keyword>Cervical cancer</keyword>
  <keyword>Magnetic resonance fingerprinting</keyword>
  <keyword>Precision medicine</keyword>
  <keyword>Radiomics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

